EUVIMEDOdkrijte EUVIMED
ÜbersichtsarbeitOpen access

100 years of glucagon and 100 more

Nicolai J Wewer Albrechtsen, Jens J Holst, Alan D Cherrington, Brian Finan, Lise Lotte Gluud, E Danielle Dean, Jonathan E Campbell, Stephen R Bloom, Tricia M-M Tan, Filip K Knop, Timo D Müller

Diabetologia · 2023

DOI: 10.1007/s00125-023-05947-y ↗

At a glance

Übersichtsarbeit in Diabetologia, 2023. Written by Nicolai J Wewer Albrechtsen and 10 co-authors. Institution: Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark. nicolai.albrechtsen…. Major MEDLINE topics: Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease, Hyperglycemia. Cited 117 times so far (Crossref); 127 references. The full text is freely available in PubMed Central. Funded by: NIDDK NIH HHS, Deutsche Forschungsgemeinschaft, Novo Nordisk Fonden.

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

The peptide hormone glucagon, discovered in late 1922, is secreted from pancreatic alpha cells and is an essential regulator of metabolic homeostasis. This review summarises experiences since the discovery of glucagon regarding basic and clinical aspects of this hormone and speculations on the future directions for glucagon biology and glucagon-based therapies. The review was based on the international glucagon conference, entitled 'A hundred years with glucagon and a hundred more', held in Copenhagen, Denmark, in November 2022. The scientific and therapeutic focus of glucagon biology has mainly been related to its role in diabetes. In type 1 diabetes, the glucose-raising properties of glucagon have been leveraged to therapeutically restore hypoglycaemia. The hyperglucagonaemia evident in type 2 diabetes has been proposed to contribute to hyperglycaemia, raising questions regarding underlying mechanism and the importance of this in the pathogenesis of diabetes. Mimicry experiments of glucagon signalling have fuelled the development of several pharmacological compounds including glucagon receptor (GCGR) antagonists, GCGR agonists and, more recently, dual and triple receptor agonists combining glucagon and incretin hormone receptor agonism. From these studies and from earlier observations in extreme cases of either glucagon deficiency or excess secretion, the physiological role of glucagon has expanded to also involve hepatic protein and lipid metabolism. The interplay between the pancreas and the liver, known as the liver-alpha cell axis, reflects the importance of glucagon for glucose, amino acid and lipid metabolism. In individuals with diabetes and fatty liver diseases, glucagon's hepatic actions may be partly impaired resulting in elevated levels of glucagonotropic amino acids, dyslipidaemia and hyperglucagonaemia, reflecting a new, so far largely unexplored pathophysiological phenomenon termed 'glucagon resistance'. Importantly, the hyperglucagonaemia as part of glucagon resistance may result in increased hepatic glucose production and hyperglycaemia. Emerging glucagon-based therapies show a beneficial impact on weight loss and fatty liver diseases and this has sparked a renewed interest in glucagon biology to enable further pharmacological pursuits.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Non-alcoholic Fatty Liver DiseaseHyperglycemiaHumansGlucagonGlucoseAmino Acids

Author keywords

Amino acidsCo-agonistsDiabetesGCGRGlucagonGlucagon receptorGluconeogenesisNAFLDReview

Substances

GlucagonGlucoseAmino Acids

Authors and institutions

  • Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark. nicolai.albrechtsen@regionh.dk.
  • Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. nicolai.albrechtsen@regionh.dk.
  • Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN, USA.
  • Novo Nordisk Research Center Indianapolis, Indianapolis, IN, USA.

Funding

  • NIDDK NIH HHS
  • Deutsche Forschungsgemeinschaft
  • Novo Nordisk Fonden
  • European Foundation for the Study of Diabetes
  • H2020 European Research Council
  • Deutsche Diabetes Gesellschaft
  • Danmarks Frie Forskningsfond
  • National Institute for Health and Care Research

Cite

APA

Wewer Albrechtsen, N. J., Holst, J. J., Cherrington, A. D., Finan, B., Gluud, L. L., Dean, E. D., Campbell, J. E., Bloom, S. R., Tan, T. M., Knop, F. K., & Müller, T. D. (2023). 100 years of glucagon and 100 more. Diabetologia. https://doi.org/10.1007/s00125-023-05947-y

Vancouver

Wewer Albrechtsen NJ, Holst JJ, Cherrington AD, Finan B, Gluud LL, Dean ED, et al. 100 years of glucagon and 100 more. Diabetologia. 2023. doi:10.1007/s00125-023-05947-y

BibTeX
@article{WewerAlbrechtsen2023,
  author = {Wewer Albrechtsen, Nicolai J and Holst, Jens J and Cherrington, Alan D and Finan, Brian and Gluud, Lise Lotte and Dean, E Danielle and Campbell, Jonathan E and Bloom, Stephen R and Tan, Tricia M-M and Knop, Filip K and Müller, Timo D},
  title = {100 years of glucagon and 100 more},
  journal = {Diabetologia},
  year = {2023},
  doi = {10.1007/s00125-023-05947-y}
}
Start for free →